Recombinant Human Intestinal Trefoil Factor (rhITF) Oral Spray For Prophylaxis Of Chemotherapy-induced Oral Mucositis

The GI Company, Inc., a privately held developer of gastrointestinal therapeutics, announced that an abstract detailing combined results from its Phase I and Phase II clinical trials has been accepted for a poster presentation at the Multinational Association of Supportive Care in Cancer’s and the International Society of Oral Oncology’s 2008 International Symposium on Supportive Care in Cancer (MASCC / ISOO). The symposium takes place June 26-28, 2008 at the Hilton Hotel Houston, Texas.

More: continued here

Filed under: GastroIntestinal / Gastroentorology on April 8th, 2008